Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the show, talked the big game, didn’t deliver.”

A stock market chart. Photo by Arturo A on Pexels

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that uses automation, data science, and AI to accelerate drug discovery. The company develops treatments for genetic, infectious, and cancer-related diseases. During the December 4, 2025, episode’s lightning round, a caller asked about the stock, and the Mad Money host replied:

I’m telling you, I am myself confounded by it. The stock has been horrendous. We gotta put that right on the table. I’m talking about horrendous, okay? So I do not like to recommend horrendous stocks. It is so low that it comes in under the category of speculative. As long as you’re willing to take the pain, they can’t, you know, you said it, they have a lot of money, but wow, I have to tell you, bad taste in my mouth. Bad.

While we acknowledge the risk and potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.